Article is below this top vid 🛑

President Donald Trump is reportedly eyeing reclassifying marijuana as a less dangerous drug, a move that could expand medical marijuana research and ease industry restrictions. Former President Joe Biden was considering such a classification change that would have also made it easier to buy and sell weed before losing last year’s presidential election to Trump. Pot companies have poured millions of dollars into Trump’s political groups and have hired some of Washington’s top lobbyists and advisers to Trump, according to the Wall Street Journal.

Trump’s Visionary Push: Reclassifying Marijuana as Less Dangerous While Cannabis Moguls Rally Behind the America First Agenda

In a riveting press conference captured in a recent video, President Donald Trump signaled his openness to reclassifying marijuana from its current Schedule I status—equating it with deadly drugs like heroin—to the less restrictive Schedule III, alongside substances like ketamine and codeine. Trump stated, “We’re looking at reclassification and we’ll make a determination over the next few weeks,” emphasizing potential medical benefits for pain relief while acknowledging concerns about broader use. This pragmatic approach, as highlighted in the footage, underscores Trump’s commitment to cutting bureaucratic red tape, expanding research, and respecting states’ rights—hallmarks of his America First policies that have resonated with conservatives weary of federal overreach. Trump’s consideration comes at a pivotal time, as the cannabis industry, long stifled by outdated regulations, poured millions into his campaign and political groups, recognizing him as the leader who could deliver real reform.

Unlike the Biden-Harris administration’s empty promises and stalled efforts, Trump’s business acumen positions him to unlock economic potential in the $34 billion sector, creating jobs and tax revenue without surrendering to leftist decriminalization chaos. The reclassification would be a game-changer: moving marijuana to Schedule III would ease criminal penalties, allow tax deductions for businesses, and facilitate banking services currently denied due to federal prohibitions. As Trump noted in the video, he’s heard “great things” about medical applications, aligning with conservative values of innovation and personal responsibility. This isn’t about promoting recreational highs—it’s about enabling scientific research into treatments for veterans’ pain, epilepsy, and chronic conditions, areas where foreign nations have outpaced America under Democrat inaction. Conservatives have long argued that the War on Drugs’ blanket approach failed, bloating government and ignoring states’ successes with medical marijuana. Trump’s potential move echoes his first-term skepticism of overregulation, promising to slash the DEA’s grip and empower states. continued below this next clip

Matt Gaetz applauds President Trump’s push to reschedule marijuana: “MAGA hats in line at the dispensary. Patriots buying pre-rolls called ‘1776 Freedom Kush.’ Beautiful… There are still people clutching their pearls, saying, ‘But marijuana is a gateway drug!’ So is Mountain Dew if you drink enough of it.”

Matt Gaetz applauds President Trump’s push to reschedule marijuana: “MAGA hats in line at the dispensary. Patriots buying pre-rolls called ‘1776 Freedom Kush.’ Beautiful… There are still people clutching their pearls, saying, ‘But marijuana is a gateway drug!’ So is Mountain Dew… pic.twitter.com/6z66uA7C2v

— One America News (@OANN) August 12, 2025

As one report detailed, this could “cut red tape, enabling scientific study, and respecting states that already legalized medical cannabis.” Rep. Greg Steube (R-FL) reintroduced the Marijuana 1-to-3 Act to formalize this, calling current classifications “absurd” and urging the Trump administration to act swiftly. The cannabis industry’s backing of Trump is no coincidence—they see him as the antidote to Biden’s bureaucratic quagmire. Pot companies donated millions to Trump’s PACs and hired top lobbyists, including his former advisors, to push for reform. At a New Jersey fundraiser, Trulieve CEO Kim Rivers directly lobbied Trump, highlighting how reclassification would boost the economy and medical access. Rivers’ company alone contributed $1 million to Trump’s inauguration, signaling deep investment in his pro-business agenda. This support surged during the 2024 election, with industry leaders frustrated by Biden’s unfulfilled promises—his DOJ proposed reclassification in May 2024 but dragged its feet, leaving businesses in limbo.

Be prepared for anything, including lockdowns with your own Emergency Med kit – see Wellness Emergency Kit (includes Ivermectin and other essential drugs, guide book, much more… peace of mind for you and your family) 🛑 – Dr. McCullough’s company! – Sponsor

High-profile conservatives and athletes amplified the call. Boxing legend Mike Tyson, a cannabis entrepreneur, urged Trump to reclassify, stating it “deserves bipartisan support” and shouldn’t be deemed more dangerous than fentanyl. NBA star Kevin Durant joined Tyson and others in a letter pressing for Schedule III status, emphasizing banking reforms for licensed businesses. These endorsements reflect a right-wing shift: conservatives like Sen. Michael Lazzara (R-NC) sided with Trump, publishing op-eds endorsing rescheduling as a “common-sense” step for medical advancement. Trump’s allies in Congress and beyond echo this. Former NFL star Ricky Williams met with White House officials to discuss how Biden “fell short” but Trump could deliver on Schedule III. Influential voices like DC_Draino called it a “no brainer,” maintaining penalties while unlocking research to “save lives.” Gunther Eagleman, a former police officer, supported Trump, arguing rescheduling would lead in medical research without endorsing abuse.

Even Matt Gaetz, Trump’s first AG pick, advocated going beyond Schedule III to prevent Big Pharma dominance, protecting small businesses. This industry backing paid off: cannabis stocks soared on news of Trump’s deliberations, with gains up to 22% for companies like Trulieve and Tilray. Executives like those at Flowhub predicted lower taxes and growth, reinvesting in tech to compete globally. Trump’s “80-20 issue” comment at the fundraiser—referring to broad support—highlights why producers bet on him: nearly 70% of Republicans agree, per polls. Critics on the right warn against full legalization’s pitfalls, like public odor and crime spikes in blue states, but Trump’s targeted reclassification avoids those traps. It maintains federal controls while dismantling Nixon-era overreach, aligning with conservative principles of limited government. As one analyst noted, this could “shake up the $34B industry” without surrendering to Democrat chaos. Biden’s failures fueled this shift: his administration proposed but botched implementation, mocked by Trump’s camp as typical incompetence.

How can you move your 401K to Gold penalty free? Get the answer and more with Goldco’s exclusive Gold IRA Beginner’s Guide. Click here now! – Goldco

Industry leaders, tired of delays, turned to Trump, who delivered on promises like tax cuts and deregulation in his first term. This policy could cement Trump’s legacy as the president who modernized drug laws for the betterment of Americans—boosting jobs, research, and freedom. With decisions imminent, conservatives watch eagerly as Trump, backed by industry patriots, charts a sensible path forward.